World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
169
Citations
132533
World Ranking
897
National Ranking
533

Immunology

D-Index
173
Citations
141771
World Ranking
48
National Ranking
35

Medicine

D-Index
173
Citations
141902
World Ranking
468
National Ranking
276

James P. Allison publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where James P. Allison sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 587 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

James P. Allison D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where James P. Allison sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 173 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2019 - Benjamin Franklin Medal, Franklin Institute
  • 2019 - Distinguished Fellows of the American Association of Immunologists (AAI)
  • 2018 - King Faisal Prize
  • 2018 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for pioneering a novel and effective strategy to harness the immune system for treating solid tumor cancers.
  • 2018 - Nobel Prize for their discovery of cancer therapy by inhibition of negative immune regulation
  • 2018 - Albany Medical Center Prize in Medicine and Biomedical Research
  • 2018 - Jessie Stevenson Kovalenko Medal, US National Academy of Sciences For important medical discoveries related to the body’s immune response to tumors.
  • 2017 - Fellow of the American Academy of Arts and Sciences
  • 2017 - BBVA Foundation Frontiers of Knowledge Award
  • 2015 - Paul Ehrlich and Ludwig Darmstaedter Prize
  • 2014 - Louisa Gross Horwitz Prize, Columbia University
  • 2014 - Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR)
  • 2014 - Breakthrough Prize in Life Sciences for the discovery of T cell checkpoint blockade as effective cancer therapy.
  • 2014 - Canada Gairdner International Award
  • 2011 - American Association of Immunologists Lifetime Achievement Award
  • 2011 - AAI Lifetime Achievement Award, American Association of Immunologists
  • 2008 - AAI-Steinman Award for Human Immunology Research, American Association of Immunologists
  • 2007 - Member of the National Academy of Medicine (NAM)
  • 2006 - Fellow of the American Association for the Advancement of Science (AAAS)
  • 1997 - Member of the National Academy of Sciences
  • 1930 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

James P. Allison is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine with a significant concentration in immunology and microbiology.

The scientist has contributed extensively to the fields of oncology, immunology, pulmonary and respiratory medicine, molecular biology, and epidemiology. Their main research topics include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immune cell function and interaction, immunotherapy and immune responses, immune cells in cancer, pancreatic and hepatic oncology research, and cancer, stress, anesthesia, and immune response.

James P. Allison has published numerous papers in prominent journals. Some recent publications are:

  • Immune checkpoint therapy-current perspectives and future directions, 2023, Cell
  • Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, 2021, Science
  • The Next Decade of Immune Checkpoint Therapy, 2021, Cancer Discovery
  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Dissecting the mechanisms of immune checkpoint therapy, 2020, Nature reviews. Immunology

Frequent co-authors in their works include:

  • Padmanee Sharma
  • Sreyashi Basu
  • Jennifer A. Wargo
  • Shalini S. Yadav
  • Sumit K. Subudhi

The most common venues for their publications include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Cancer Immunology Research
  • Clinical Cancer Research
  • Nature

Throughout their career, James P. Allison has received various awards, including:

  • Distinguished Fellows of the American Association of Immunologists (AAI), 2019
  • Benjamin Franklin Medal, Franklin Institute, 2019
  • Albany Medical Center Prize in Medicine and Biomedical Research, 2018
  • Jessie Stevenson Kovalenko Medal, US National Academy of Sciences, 2018, for important medical discoveries related to the body's immune response to tumors
  • Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson, 2018, for pioneering a novel and effective strategy to harness the immune system for treating solid tumor cancers
  • Nobel Prize, 2018, for their discovery of cancer therapy by inhibition of negative immune regulation
  • King Faisal Prize, 2018
  • Fellow of the American Academy of Arts and Sciences, 2017
  • BBVA Foundation Frontiers of Knowledge Award, 2017
  • Paul Ehrlich and Ludwig Darmstaedter Prize, 2015
  • Louisa Gross Horwitz Prize, Columbia University, 2014
  • Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR), 2014
  • Breakthrough Prize in Life Sciences, 2014, for the discovery of T cell checkpoint blockade as effective cancer therapy
  • Canada Gairdner International Award, 2014
  • American Association of Immunologists Lifetime Achievement Award, 2011
  • AAI Lifetime Achievement Award, American Association of Immunologists, 2011
  • AAI-Steinman Award for Human Immunology Research, American Association of Immunologists, 2008
  • Member of the National Academy of Medicine (NAM), 2007
  • Fellow of the American Association for the Advancement of Science (AAAS), 2006
  • Member of the National Academy of Sciences, 1997
  • Fellow of the American Association for the Advancement of Science (AAAS), 1930

Best Publications

  • The future of immune checkpoint therapy

    Padmanee Sharma;James P. Allison

  • Restoring function in exhausted CD8 T cells during chronic viral infection.

    Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu

  • Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben

  • Enhancement of antitumor immunity by CTLA-4 blockade.

    Dana R. Leach;Matthew F. Krummel;James P. Allison

  • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

    Spencer C. Wei;Colm R. Duffy;James P. Allison

  • Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

    Berna C. Özdemir;Berna C. Özdemir;Tsvetelina Pentcheva-Hoang;Julienne L. Carstens;Xiaofeng Zheng

  • CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

    Matthew F. Krummel;James P. Allison

  • Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

    Padmanee Sharma;James P. Allison

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

    Michael A. Postow;Margaret K. Callahan;Margaret K. Callahan;Christopher A. Barker;Christopher A. Barker;Yoshiya Yamada;Yoshiya Yamada

  • Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

    Matthew M. Gubin;Xiuli Zhang;Heiko Schuster;Etienne Caron

  • CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

    Fiona A. Harding;James G. McArthur;Jane A. Gross;David H. Raulet

  • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

    Michael A. Curran;Welby Montalvo;Hideo Yagita;James P. Allison

  • Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

    Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu

  • The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

    Martin A. Cheever;Martin A. Cheever;James P. Allison;Andrea S. Ferris;Olivera J. Finn

  • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

    Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda

  • Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

    Sarah E. Townsend;James P. Allison

  • Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

    Andrea van Elsas;Andrea van Elsas;Arthur A. Hurwitz;James P. Allison

  • Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

    R. P.M. Sutmuller;L. M. Van Duivenvoorde;A. Van Elsas;T. N.M. Schumacher

  • Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

    Hirokazu Matsushita;Hirokazu Matsushita;Matthew D. Vesely;Daniel C. Koboldt;Charles G. Rickert

Frequent Co-Authors

Padmanee Sharma
Padmanee Sharma The University of Texas MD Anderson Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Jianda Yuan
Jianda Yuan MSD (United States)
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare and research careers. Many students complement their immunology knowledge by pursuing nursing degrees, which offer practical applications in patient care and disease prevention. For those without a nursing background, online RN programs for non nurses provide accessible pathways to enter the nursing field while building on scientific expertise.

Accelerated options help current registered nurses advance quickly. For instance, accelerated RN to NP programs enable nurses to become nurse practitioners in less time, enhancing clinical responsibilities and career growth. Those seeking entry-level nursing routes may consider programs like the easiest ABSN programs to get into, which allow quicker transitions from non-nursing backgrounds to a Bachelor of Science in Nursing.

Additionally, beginning a career as a Licensed Practical Nurse is another viable option, with easiest LPN programs to get into making this path more accessible. Combining these nursing pathways with immunology expertise can lead to impactful careers in healthcare, research, and public health sectors.

Best Scientists Citing James P. Allison

Trending Scientists

Recently Published Articles